Document is current

Article History

Accepted: 22 July 2024

First Online: 5 August 2024

Declarations

:

: This study was funded by Novartis Pharmaceuticals Australia.

: Financial interests: MF was employed by Novartis at the time the study was conducted. No other authors have financial interests to declare. Non-financial interests: None to declare. Maria Farris received a salary from Novartis during the study conduct. This research was part of an Industry Doctorate Program in collaboration with Novartis Pharmaceuticals Australia and the Centre for Health Economics Research and Evaluation, University of Technology Sydney. Maria Farris is now an employee of AstraZeneca Pharmaceuticals Australia.

: This study was approved for conduct under the Centre for Health Economic Research and Evaluation program ethics approval from the University of Technology Sydney Ethics Committee on September 8, 2022 (UTS HREC REF NO. ETH21-6090).

: Informed consent was obtained from all individual participants included in the study.

: The data that support the findings of this study are not openly available due to reasons of sensitivity but are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Centre for Health Economic Research and Evaluation, University of Technology Sydney, Australia.

: The code for the current study are available from the corresponding author upon reasonable request.

: Conception and methodology: Maria Farris, Stephen Goodall, Richard De Abreu Lourenco, Brendan Mulhern. Data acquisition: Maria Farris, Kathleen Manipis, Elena Meshcheriakova, Milena Lewandowska. Data analysis: Maria Farris. Interpretation of data: Maria Farris, Stephen Goodall, Richard De Abreu Lourenco, Brendan Mulhern. The first draft of the manuscript was written by Maria Farris and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and confirm the manuscript.